Orlandi Ester M, Zibellini Silvia, Pascutto Cristiana, Picone Cristina, Giardini Ilaria, Pochintesta Lara, Lazzarino Mario
Clinic of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy.
Clin Lymphoma Myeloma. 2009 Oct;9(5):390-3. doi: 10.3816/CLM.2009.n.076.
In this study, IGHV1-69 gene usage was detected in 46 out of 379 cases (12%) of chronic lymphocytic leukemia (CLL). In comparison with patients using alternative immunoglobulin heavy-chain variable (IGHV) genes, patients with IgHV1-69 CLLs more often presented at advanced stage, lacked somatic hypermutation (unmutated cases, 87% vs. 35%; P = .00001), and expressed unfavorable biologic characteristics. In 12 patients (26%), common amino acid motifs within the heavy-chain third complementarity-determining region were identified, allowing assignment to previously reported stereotyped subsets. In our study, treatment-free survival of patients with unmutated IGVH1-69 did not differ significantly from that of patients expressing unmutated alternative IGHV genes. As such, IGHV1-69 gene usage per se did not seem to be predictive of progressive disease, progression being primarily related to the unmutated IGHV profile.
在本研究中，379例慢性淋巴细胞白血病（CLL）患者中有46例（12%）检测到IGHV1-69基因使用情况。与使用其他免疫球蛋白重链可变（IGHV）基因的患者相比，IGHV1-69 CLL患者更常处于疾病晚期，缺乏体细胞超突变（未突变病例，87%对35%；P = 0.00001），且表现出不良生物学特征。在12例患者（26%）中，鉴定出重链第三个互补决定区内的常见氨基酸基序，从而可归类到先前报道的定型亚组。在我们的研究中，未突变IGVH1-69患者的无治疗生存期与表达未突变其他IGHV基因的患者相比无显著差异。因此，IGHV1-69基因使用本身似乎不能预测疾病进展，疾病进展主要与未突变的IGHV谱相关。
